Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on the generation and assessment of investment cases in the biopharm, medtech, diagnostics and digital health sectors and supports transaction execution and fund management.
Prior to joining Gilde, Stefan worked at Merck KGaA for two years. As part of the Global Graduate Program he completed several international assignments, most notably with the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions.
Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK) where he developed a bicyclic peptide based drug discovery platform.
He is a Swiss citizen based in Gilde’s Utrecht office.